<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03983317</url>
  </required_header>
  <id_info>
    <org_study_id>CRD-12-1176-01</org_study_id>
    <secondary_id>R43AA027188-01</secondary_id>
    <nct_id>NCT03983317</nct_id>
  </id_info>
  <brief_title>Pilot Evaluation of the Empower Neuromodulation System in AUD Patients</brief_title>
  <official_title>Pilot Evaluation of the Empower Neuromodulation System in Alcohol Use Disorder (AUD) Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Theranova, L.L.C.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Alcohol Abuse and Alcoholism (NIAAA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Northern California Institute of Research and Education</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Theranova, L.L.C.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the effects of peripheral nerve stimulation on alcohol craving and&#xD;
      consumption in participants with alcohol use disorder (AUD). This is a pilot investigation in&#xD;
      which all participants will receive the active treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Alcohol use disorder (AUD) is a major public health concern, affecting over 16 million&#xD;
      Americans. Peripheral nerve stimulation via acupuncture has been shown to directly decrease&#xD;
      alcohol craving and self-administration. TheraNova has developed the Empower Neuromodulation&#xD;
      System, a non-invasive, portable transcutaneous electrical nerve stimulation (TENS) device&#xD;
      intended to stimulate peripheral nerves for the treatment of AUD. In this study, we will&#xD;
      conduct a cross-over, home-use study in participants with AUD. Participants will have a&#xD;
      one-week control period with no treatment followed by two weeks of twice daily treatment with&#xD;
      the Empower device. We will evaluate endpoints for safety and effectiveness.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 20, 2019</start_date>
  <completion_date type="Actual">March 26, 2020</completion_date>
  <primary_completion_date type="Actual">March 26, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>All participants will have a one-week control period with no treatment followed by two weeks of twice daily Empower treatment.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Mean Number of Alcoholic Drinks Consumed Per Day</measure>
    <time_frame>Baseline week and Week 2 of the treatment phase</time_frame>
    <description>Change in the self-reported average daily consumption over the final week (Week 2) of the treatment phase compared to the week of the pre-treatment baseline phase.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Adverse Events</measure>
    <time_frame>Through study completion, an average of 3 weeks</time_frame>
    <description>Safety assessment via device-related adverse events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Decrease in Mean Alcohol Craving Intensity</measure>
    <time_frame>Baseline week and Week 2 of the treatment phase</time_frame>
    <description>Change in self-reported average alcohol craving intensity via 100-mm visual-analog scale (VAS). The VAS has a minimum score of 0 (no craving) and a maximum score of 100 (severe craving). We compared the average daily craving intensity over the final week (Week 2) of the treatment phase compared to the week of the pre-treatment baseline phase.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Usability</measure>
    <time_frame>Study completion, at approximately 3 weeks</time_frame>
    <description>System Usability Scale (SUS) survey to evaluate usability. The SUS is a 10-item self-report survey (each question is answered on a 5-point Likert scale) which measures usability. An SUS score of 68 is considered average, whereas SUS=80 is the 90th percentile score (&quot;excellent&quot;).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Alcohol Use Disorder</condition>
  <arm_group>
    <arm_group_label>Baseline</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>For the first week of the study, participants will not administer treatment with the Empower device. Participants will complete surveys to establish baseline values for each participant.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Active treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will self-administer treatment with the Empower device two times daily for two weeks. Participants will complete surveys over the two-week period to evaluate the effects of the Empower treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Empower Neuromodulation System</intervention_name>
    <description>Transcutaneous electrical nerve stimulation</description>
    <arm_group_label>Active treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Is male or female â‰¥ 21 year of age at Visit 1&#xD;
&#xD;
          -  Has a current diagnosis of alcohol use disorder per DSM-5 by clinician assessment&#xD;
&#xD;
          -  Endorses Criterion 4 in DSM-5&#xD;
&#xD;
          -  Has a desire to maintain abstinence or, if not abstinent, a desire to reduce or quit&#xD;
             alcohol use&#xD;
&#xD;
          -  Has a breath alcohol concentration of 0.00% at enrollment&#xD;
&#xD;
          -  Is able to provide informed consent&#xD;
&#xD;
          -  Is able to understand spoken and written English&#xD;
&#xD;
          -  Is capable and willing to follow all study-related procedures&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Has been diagnosed with unstable psychosis, epilepsy, peripheral neuropathy, or nerve&#xD;
             damage&#xD;
&#xD;
          -  Requires acute medical detoxification from alcohol based on a score of 12 or more on&#xD;
             the Clinical Institute Withdrawal Assessment of Alcohol Scale (CIWA-AD)&#xD;
&#xD;
          -  Has implanted electrical and/or neurostimulator device (e.g. pacemaker, defibrillator,&#xD;
             vagal neurostimulator, deep brain stimulator, spinal stimulator, sacral stimulator,&#xD;
             bone growth stimulator, or cochlear implant)&#xD;
&#xD;
          -  Has an electrically conductive metal object (e.g. jewelry) that cannot be removed from&#xD;
             the palm and will directly contact the gel electrodes of the Empower Neuromodulation&#xD;
             System&#xD;
&#xD;
          -  Will not, for the duration of the participation in the study, have a living situation&#xD;
             that provides regular access to an electrical outlet.&#xD;
&#xD;
          -  Is pregnant, breastfeeding, or unwilling to practice birth control during&#xD;
             participation in the study&#xD;
&#xD;
          -  Has used an investigational drug/device therapy within the past 4 weeks&#xD;
&#xD;
          -  Is deemed unsuitable for enrollment in the study by the PI&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Jaasma</last_name>
    <role>Study Director</role>
    <affiliation>Theranova, L.L.C.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>NCIRE</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>June 10, 2019</study_first_submitted>
  <study_first_submitted_qc>June 10, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 12, 2019</study_first_posted>
  <results_first_submitted>September 25, 2020</results_first_submitted>
  <results_first_submitted_qc>September 25, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">October 20, 2020</results_first_posted>
  <last_update_submitted>November 12, 2020</last_update_submitted>
  <last_update_submitted_qc>November 12, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alcoholism</mesh_term>
    <mesh_term>Alcohol Drinking</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>December 18, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/17/NCT03983317/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Participants completed the Baseline Phase first, so participants who did not complete the Baseline Phase did not start the Treatment Phase.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Active Treatment</title>
          <description>For the first week of the study, participants did not administer treatment with the Empower device. In this one-week Baseline Phase, participants only completed surveys to establish baseline values. In the final two weeks of the study, participants self-administered treatment with the Empower device two times daily. Participants completed surveys over the two-week period to evaluate the effects of the Empower treatment.&#xD;
Empower Neuromodulation System: Transcutaneous electrical nerve stimulation</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Active Treatment</title>
          <description>For the first week of the study, participants did not administer treatment with the Empower device. In this one-week Baseline Phase, participants only completed surveys to establish baseline values. In the final two weeks of the study, participants self-administered treatment with the Empower device two times daily. Participants completed surveys over the two-week period to evaluate the effects of the Empower treatment.&#xD;
Empower Neuromodulation System: Transcutaneous electrical nerve stimulation</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="25"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58" lower_limit="34" upper_limit="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Mean Number of Alcoholic Drinks Consumed Per Day</title>
        <description>Change in the self-reported average daily consumption over the final week (Week 2) of the treatment phase compared to the week of the pre-treatment baseline phase.</description>
        <time_frame>Baseline week and Week 2 of the treatment phase</time_frame>
        <population>Participants who completed the study</population>
        <group_list>
          <group group_id="O1">
            <title>Active Treatment</title>
            <description>For the first week of the study, participants did not administer treatment with the Empower device. In this one-week Baseline Phase, participants only completed surveys to establish baseline values. In the final two weeks of the study, participants self-administered treatment with the Empower device two times daily. Participants completed surveys over the two-week period to evaluate the effects of the Empower treatment.&#xD;
Empower Neuromodulation System: Transcutaneous electrical nerve stimulation</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Mean Number of Alcoholic Drinks Consumed Per Day</title>
          <description>Change in the self-reported average daily consumption over the final week (Week 2) of the treatment phase compared to the week of the pre-treatment baseline phase.</description>
          <population>Participants who completed the study</population>
          <units>Change in alcoholic drinks per day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.1" spread="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>We tested if the average drinks consumed was statistically different in Week 2 of the Treatment Phase vs. the Baseline Phase. This was evaluated via a paired t-test.</non_inferiority_desc>
            <p_value>0.026</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>Paired t-test</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Adverse Events</title>
        <description>Safety assessment via device-related adverse events</description>
        <time_frame>Through study completion, an average of 3 weeks</time_frame>
        <population>All participants</population>
        <group_list>
          <group group_id="O1">
            <title>Active Treatment</title>
            <description>For the first week of the study, participants did not administer treatment with the Empower device. In this one-week Baseline Phase, participants only completed surveys to establish baseline values. In the final two weeks of the study, participants self-administered treatment with the Empower device two times daily. Participants completed surveys over the two-week period to evaluate the effects of the Empower treatment.&#xD;
Empower Neuromodulation System: Transcutaneous electrical nerve stimulation</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Events</title>
          <description>Safety assessment via device-related adverse events</description>
          <population>All participants</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Decrease in Mean Alcohol Craving Intensity</title>
        <description>Change in self-reported average alcohol craving intensity via 100-mm visual-analog scale (VAS). The VAS has a minimum score of 0 (no craving) and a maximum score of 100 (severe craving). We compared the average daily craving intensity over the final week (Week 2) of the treatment phase compared to the week of the pre-treatment baseline phase.</description>
        <time_frame>Baseline week and Week 2 of the treatment phase</time_frame>
        <population>Participants who completed the study</population>
        <group_list>
          <group group_id="O1">
            <title>Active Treatment</title>
            <description>For the first week of the study, participants did not administer treatment with the Empower device. In this one-week Baseline Phase, participants only completed surveys to establish baseline values. In the final two weeks of the study, participants self-administered treatment with the Empower device two times daily. Participants completed surveys over the two-week period to evaluate the effects of the Empower treatment.&#xD;
Empower Neuromodulation System: Transcutaneous electrical nerve stimulation</description>
          </group>
        </group_list>
        <measure>
          <title>Decrease in Mean Alcohol Craving Intensity</title>
          <description>Change in self-reported average alcohol craving intensity via 100-mm visual-analog scale (VAS). The VAS has a minimum score of 0 (no craving) and a maximum score of 100 (severe craving). We compared the average daily craving intensity over the final week (Week 2) of the treatment phase compared to the week of the pre-treatment baseline phase.</description>
          <population>Participants who completed the study</population>
          <units>Change in units on 100-mm VAS scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13" spread="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>We tested if the average craving intensity was statistically different in Week 2 of the Treatment Phase vs. the Baseline Phase. This was evaluated via a paired t-test.</non_inferiority_desc>
            <p_value>0.001</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>Paired t-test</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Usability</title>
        <description>System Usability Scale (SUS) survey to evaluate usability. The SUS is a 10-item self-report survey (each question is answered on a 5-point Likert scale) which measures usability. An SUS score of 68 is considered average, whereas SUS=80 is the 90th percentile score (&quot;excellent&quot;).</description>
        <time_frame>Study completion, at approximately 3 weeks</time_frame>
        <population>Participants who completed the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Active Treatment</title>
            <description>For the first week of the study, participants did not administer treatment with the Empower device. In this one-week Baseline Phase, participants only completed surveys to establish baseline values. In the final two weeks of the study, participants self-administered treatment with the Empower device two times daily. Participants completed surveys over the two-week period to evaluate the effects of the Empower treatment.&#xD;
Empower Neuromodulation System: Transcutaneous electrical nerve stimulation</description>
          </group>
        </group_list>
        <measure>
          <title>Usability</title>
          <description>System Usability Scale (SUS) survey to evaluate usability. The SUS is a 10-item self-report survey (each question is answered on a 5-point Likert scale) which measures usability. An SUS score of 68 is considered average, whereas SUS=80 is the 90th percentile score (&quot;excellent&quot;).</description>
          <population>Participants who completed the study.</population>
          <units>Score on the SUS survey scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76" spread="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>3 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Active Treatment (AEs Occurred During the Two-week Treatment Phase)</title>
          <description>For the first week of the study, participants did not administer treatment with the Empower device. In this one-week Baseline Phase, participants only completed surveys to establish baseline values. In the final two weeks of the study, participants self-administered treatment with the Empower device two times daily. Participants completed surveys over the two-week period to evaluate the effects of the Empower treatment.&#xD;
Empower Neuromodulation System: Transcutaneous electrical nerve stimulation</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Head injury</sub_title>
                <description>Slip/fall with head injury. Determined to not be device-related</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <description>Determined to not be device-related</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Vice President of Research and Development</name_or_title>
      <organization>TheraNova, LLC</organization>
      <phone>415-926-8616</phone>
      <email>clinicalstudy@theranova.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

